What Is Psilocybin-Assisted Therapy? A Clear Guide to Legality, Science, and Access

Psychedelic-assisted therapy, including psilocybin therapy, is being studied as an alternative for those who haven’t responded to conventional treatment. Get informed here!

In 2020, Oregon became the first U.S. state to legalize supervised psilocybin use. Colorado followed soon after. Around the same time, the FDA granted psilocybin “breakthrough therapy” status for major depressive disorder. 

What was once relegated to counterculture is now being studied in some of the world’s leading research institutions for its potential to treat depression, PTSD, addiction, and end-of-life anxiety. 

The Search for New Depression Treatments

Depression remains one of the most debilitating mental health conditions worldwide. An estimated 47.8 million Americans suffer from depression. Among individuals treated for major depressive disorder (MDD), approximately 30% may develop treatment-resistant depression (TRD), meaning their symptoms do not adequately improve after multiple standard interventions.

When the standard protocols fail, the question becomes unavoidable: what else is possible?

Psychedelic-assisted therapy, including psilocybin therapy, is being studied as an alternative for those who haven’t responded to conventional treatment. In early trials for treatment-resistant depression, response rates have approached 50–60%, which is notably high. 

Psilocybin emerges as a potential solution to address the need for new depression treatments.

What is Psilocybin-Assisted Therapy

It’s important to note that psilocybin-assisted therapy is not recreational use repackaged. It’s a structured therapeutic approach that combines the administration of psilocybin and professional therapeutic support.

Psilocybin-assisted therapy is often misunderstood because terms such as “decriminalized,” “legal,” and “psilocybin therapy” are used interchangeably, even though they describe fundamentally different legal and therapeutic realities.

Psilocybin Decriminalization

Decriminalization does not make psilocybin legal. It generally means that possession of small amounts is treated as a low enforcement priority or that criminal penalties have been reduced or removed. Psilocybin remains illegal under federal law in the United States, and decriminalization policies do not automatically create access to therapeutic programs.

Medical Use

Psilocybin is not currently approved by the FDA as a prescription medication. Although it has received “breakthrough therapy” designation for certain conditions such as major depressive disorder, that status does not guarantee medical access.

Clinical Research

Psilocybin can be legally studied in approved research settings under strict regulatory oversight. Universities and medical centers conduct trials under federal approval, with carefully designed protocols that include preparation, supervised administration, and integration therapy. 

How Does Psilocybin-Assisted Therapy Work?

At its core, psilocybin-assisted therapy relies on a naturally occurring psychedelic compound: psilocybin.

Meet the Psilocybin Molecule

Psilocybin is the primary psychoactive compound found in certain species of mushrooms, commonly referred to as “magic mushrooms.” On its own, psilocybin is biologically inactive. It is what pharmacologists call a prodrug — a substance that becomes active only after the body metabolizes it.

Once ingested, psilocybin is converted into psilocin. Psilocin then interacts primarily with serotonin receptors in the brain, especially the 5-HT2A receptor. Serotonin is a neurotransmitter involved in mood, perception, and cognition. Its activation is strongly associated with the altered states of consciousness produced by psychedelics.

This receptor activity can lead to shifts in perception, emotion, and patterns of thought, all effects commonly described as a psychedelic experience.

Psilocybin-Assisted Therapy: What the Therapeutic Process Typically Involves

In most models, psilocybin-assisted therapy includes three core phases: preparation, supervised administration, and integration.

1. Preparation

At the start, participants meet with the therapist to build rapport and establish psychological safety. This foundation of trust is essential.

Preparation sessions typically involve a detailed discussion of the participant’s mental health history, current symptoms, treatment goals, and intentions for the experience. The therapist may also explain what to expect during the session and discuss strategies for navigating challenging emotions should they arise.

This phase can last several hours across one or more sessions.

2. Supervised Session

The psilocybin session takes place in a controlled, supportive setting. Participants receive psilocybin and then remain under supervision for the duration of the experience, which commonly lasts between six and eight hours.

During this time, trained facilitators or licensed mental health professionals monitor safety and provide psychological support as needed. The environment is typically structured to minimize external distractions and promote inward focus.

3. Integration

Integration is often considered one of the most important phases of the process. These sessions usually occur the day after the experience, though additional meetings may follow.

During integration, the therapist and participant reflect on the experience, explore its emotional and psychological meaning, and identify how insights can be applied in daily life. The aim is not simply to recount what happened, but to translate the experience into sustainable change.

To learn more about how integration supports long-term psychological change after a psilocybin experience, visit our detailed guide on psychedelic integration.

Psilocybin-Assisted Therapy in Clinical Research

Universities and medical centers continue to study psilocybin-assisted therapy for conditions such as major depressive disorder, treatment-resistant depression, end-of-life distress, and substance use disorders. Participation is limited to eligible volunteers who meet specific inclusion criteria.

For example, the University of California, San Francisco (UCSF) is conducting a multicenter, randomized, triple-blind Phase 2 clinical trial evaluating the efficacy and safety of psilocybin-assisted therapy compared to an active control in adults experiencing demoralization near the end of life (defined as a life expectancy of two years or less). The study aims to assess whether psilocybin-assisted therapy can meaningfully reduce existential distress in this population.

In another example, the Portland VA Health Care System in Vancouver, Washington, is studying psilocybin-assisted therapy within a residential rehabilitation treatment program. The protocol includes preparatory therapy sessions, two supervised psilocybin sessions (25–30 mg), and multiple integration sessions.

Note: Clinical programs include medical and psychological screening to reduce risk, and psilocybin-assisted therapy is not considered appropriate for individuals with certain psychiatric conditions.

Where can I do psilocybin therapy legally?

One pathway is participation in approved clinical research. A publicly available resource for identifying ongoing studies is the UC Berkeley Center for the Science of Psychedelics clinical trials map.

Outside of research settings, state-regulated access exists in Oregon through its licensed psilocybin services program, and Colorado is in the process of implementing its regulated natural medicine framework. These programs operate under state law but remain distinct from FDA-approved medical treatment.

Legal access to psilocybin remains limited and highly regulated. You can explore the current legal landscape, including state programs and federal status, in our in-depth guide to psilocybin legality.

Psilocybin-assisted therapy sits at a rare and exciting crossroads of neuroscience, psychotherapy, and drug policy reform. It is neither counterculture folklore nor established medicine, but something in between, shifting and developing — shaped in real time by research and regulation.